"The reduction in revenue due to Zyprexa patent expirations is expected to be partially offset by growth in key franchises including Cymbalta, Cialis®, Humalog®, Humulin® and Forteo®, as well as continued growth of newer products such as Effient®, Axiron® and Tradjenta®."
this implies that Axiron will be a material contributor to group revenue growth.
pretty awesome to be mentioned in the same sentence as blockbuster names like cymbalta and cialis!
- Forums
- ASX - By Stock
- brief comment from lilly on acr's axiron drug
"The reduction in revenue due to Zyprexa patent expirations is...
Featured News
Add ACR (ASX) to my watchlist
|
|||||
Last
6.6¢ |
Change
-0.003(4.35%) |
Mkt cap ! $19.18M |
Open | High | Low | Value | Volume |
6.9¢ | 6.9¢ | 6.5¢ | $50.65K | 764.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6729 | 6.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 76714 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6729 | 0.066 |
1 | 9230 | 0.065 |
1 | 100000 | 0.064 |
1 | 72727 | 0.063 |
1 | 1700 | 0.062 |
Price($) | Vol. | No. |
---|---|---|
0.070 | 76714 | 1 |
0.071 | 18601 | 1 |
0.072 | 30000 | 1 |
0.079 | 50000 | 1 |
0.080 | 215286 | 4 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |